Literature DB >> 6459759

Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.

R E Polk, B J Kline, S M Markowitz.   

Abstract

A high-performance liquid chromatographic method for the measurement of moxalactam concentrations in serum was modified to permit the simultaneous measurement of both moxalactam and cefazolin. We then studied whether the simultaneous administration of both moxalactam and cefazolin to normal subjects would produce profiles of serum concentration versus time which were the same as those obtained after the administration of each drug individually. Six healthy adults received a 30-min infusion of cefazolin (10 mg/kg), followed in 2 days by the same dose of moxalactam. After 2 days, both antibiotics were administered together. A two-compartment model was found to adequately characterize the data, and the serum concentration curve for each drug when given alone was statistically identical to that obtained after simultaneous administration. Cefazolin was found to produce a significantly greater peak serum concentration (105 +/- 14 versus 81 +/- 21 microgram/ml) and a significantly greater area under the curve (218 +/- 42 versus 157 +/- 19 . microgram h/ml). The terminal half-life of moxalactam was not significantly longer than for cefazolin (2.2 +/- 0.6 versus 2.0 +/- 0.6 h, respectively). The method of simultaneous administration may have distinct advantages over conventional methods for studies of comparative tissue penetration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6459759      PMCID: PMC181753          DOI: 10.1128/AAC.20.5.576

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

3.  Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.

Authors:  S Srinivasan; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.

Authors:  R Wise; S Baker; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

5.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

6.  Effect of protein binding on the penetration of nonmetabolized cephalosporins into atrial appendage and pericardial fluids in open-heart surgical patients.

Authors:  C H Nightingale; J J Klimek; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

7.  Cephalothin and cefamandole penetration into bone, synovial fluid, and wound drainage fluid.

Authors:  D J Schurman; H P Hirshman; D S Burton
Journal:  J Bone Joint Surg Am       Date:  1980-09       Impact factor: 5.284

8.  Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.

Authors:  T C Eickhoff; J Ehret
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

9.  Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects.

Authors:  W M Scheld; D A Spyker; G R Donowitz; W K Bolton; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

  9 in total
  4 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

2.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

3.  Penetration of moxalactam and cefazolin into atrial appendage after simultaneous intramuscular or intravenous administration.

Authors:  R E Polk; J E Smith; K Ducey; R R Lower
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

Review 4.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.